PROVIDENCE – EpiVax Inc. has out-licensed its COVID-19 vaccine candidate to EpiVax Therapeutics, based in New York.
EVT, a venture-backed company that was previously named EpiVax Oncology that is a spin-out of EpiVax Inc., will seek to raise an additional $3 million for the new vaccine program and has recently reorganized its executive team in preparation for a pipeline expansion.
Preparing for Potential Tax Changes
The upcoming 2024 election will have a major impact on tax policy, specifically provisions created…
Learn More
The vaccine, designed for frontline heath care workers, is intended to operate as “body armor” for their immune systems, to generate a T cell-mediated immune response that could reduce the risk of severe COVID-19 cases.
“The EpiVax team has done a fantastic job in the preclinical research phase,” said Dr. Anne S. De Groot, CEO, chief science officer and cofounder of EpiVax. “We are confident that EPV-CoV-19 will be safe and effective for frontline health care workers. We look forward to working with EVT to accelerate its progress to Phase I and beyond.”
EpiVax said that following a positive Pre-Investigational New Drug Application response from the Federal Drug Administration, the vaccine is headed toward clinical trials.
“EVT is pleased to welcome the COVID-19 vaccine program into our pipeline,” said Michael Princiotta, chief science officer at EVT. “We are eager to apply our vaccine platform and fundraising experience to advance EPV-CoV-19 into clinical trials.”
